Evidence map›Paper›PMID 37698416›Full record

ArticleMicrobiology spectrum2023

Discovery of novel reversible inhibitor of DprE1 based on benzomorpholine for the treatment of tuberculosis.

Wang Xiang, Hualong He, Xianjie Duan, Zhiqun He, Xinyue Xu, Mengya Liao, Fei Teng, Xiao Li, Tianwen Luo, Jumei Zeng and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Wang Xiang *State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, West China Medical School, Sichuan University , Chengdu, Sichuan, China.
Hualong He *State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, West China Medical School, Sichuan University , Chengdu, Sichuan, China.
Xianjie Duan *State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, West China Medical School, Sichuan University , Chengdu, Sichuan, China.
Zhiqun HeWest China School of Public Health and West China Fourth Hospital, Sichuan University , Chengdu, Sichuan, China.
Xinyue XuWest China School of Public Health and West China Fourth Hospital, Sichuan University , Chengdu, Sichuan, China.
Mengya LiaoCenter of Gerontology and Geriatrics, West China Hospital, Sichuan University , Chengdu, Sichuan, China.
Fei TengState Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, West China Medical School, Sichuan University , Chengdu, Sichuan, China.
Xiao LiState Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, West China Medical School, Sichuan University , Chengdu, Sichuan, China.
Tianwen LuoState Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, West China Medical School, Sichuan University , Chengdu, Sichuan, China.
Jumei ZengWest China School of Public Health and West China Fourth Hospital, Sichuan University , Chengdu, Sichuan, China.
Luoting YuState Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, West China Medical School, Sichuan University , Chengdu, Sichuan, China.
Chao GaoCenter of Infectious Diseases and Laboratory of Human Diseases and Immunotherapies and Institute of Immunology and Inflammation, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University , Chengdu, Sichuan, China.ORCID 0000-0002-2227-338X
Sichuan University · CN

Funding

the Fundermental Research Funds for the Central Universities 2019SCU12029the National Mega-Project for Innovative Drugs 2019ZX09721001the Post-Doctoral Research Project 2018HXBH036
6 · The paper itself

Abstract

importanceDrug therapy remains the cornerstone of tuberculosis (TB) treatment, yet first-line anti-tuberculosis drugs are associated with significant adverse effects that can compromise patient outcomes. Moreover, prolonged and widespread use has led to an alarming rise in drug-resistant strains of

Indexed as

antimycobacterial agentsbenzomorpholineDprE1tuberculosis

Identifiers

PMID37698416
PMCPMC10581193
OpenAlexW4386624614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.